title: Effects of renal-specific oral supplementation in malnourished hemodialysis patients.
abstract: BACKGROUND
  Protein-energy malnutrition is still a problem in patients with chronic renal failure, especially during replacement renal therapy. The chronic inflammatory status in these patients intensifies the malnutrition, as well as making treatment more complicated. The aim of the present study was to estimate the influence of oral supplementation on the nutritional status of malnourished hemodialysis (HD) patients depending on the existence of an inflammatory state.
  
  
  METHODS
  To study the influence of oral supplementation on nutrition status, 30 HD patients with protein-energy malnutrition characteristics and 25 well-nourished HD patients were enrolled in the study. Malnourished HD patients were prescribed Renilon 7.5 at an oral intake dose of 125 mL twice a day for 3 months. The nutritional status was characterized based on body mass index, Subjective Global Assessment score, serum albumin and prealbumin concentrations. The intensity of the inflammatory state was determined by C-reactive protein and interleukin-6. Serum concentrations of leptin and adiponectin were also measured.
  
  
  RESULTS
  After 3 months of supplementation, malnourished patients had an increase in prealbumin, albumin, and leptin concentrations. No statistically significant differences were observed between patients lacking inflammation and those with inflammation.
  
  
  CONCLUSIONS
  The results indicate an improvement in the nutritional status of HD patients who were prescribed an oral supplementation. Furthermore, patients with inflammatory state characteristics also benefited from Renilon 7.5 treatment.
authors.affiliation: Department of Clinical Nutrition, Medical University of Gdansk, Gdańsk, Poland. sylwia@tetra.pl
authors.forename: Sylwia
authors.initials: S
authors.lastname: Małgorzewicz
authors.forename: Przemysław
authors.initials: P
authors.lastname: Rutkowski
authors.forename: Magdalena
authors.initials: M
authors.lastname: Jankowska
authors.forename: Alicja
authors.initials: A
authors.lastname: Dębska-Ślizień
authors.forename: Bolesław
authors.initials: B
authors.lastname: Rutkowski
authors.forename: Wiesława
authors.initials: W
authors.lastname: Łysiak-Szydłowska
mesh_terms: D000328:Adult; D000368:Aged; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis / Q000378:metabolism; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy*; D015850:Interleukin-6 / Q000032:analysis / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status / Q000187:drug effects; D011502:Protein-Energy Malnutrition / Q000150:complications / Q000188:drug therapy*; D006435:Renal Dialysis; D012709:Serum Albumin
chemical_list: D015850:Interleukin-6; D020738:Leptin; D012709:Serum Albumin; D002097:C-Reactive Protein